Longitudinal tracking of FTLD: Toward developing clinical trial methodology

David S. Knopman, Bradley S. Boeve, Richard J. Caselli, Neill R. Graff-Radford, Joel H. Kramer, Mario F. Mendez, Bruce L. Miller

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Putative treatments for the frontotemporal lobar degenerations are likely to become available for testing in clinical trials in the next few years. To design clinical trials for this group of disorders, a number of conceptual, methodologic, and diagnostic issues must be resolved. This presentation reviews diagnostic criteria, instruments for longitudinal study, questions about study duration, and the possible uses of biomarkers in clinical trials. In addition, a multicenter trial is described in which some aspects of diagnosis and longitudinal measurement in the frontotemporal lobar degenerations are being specifically explored.

Original languageEnglish (US)
Pages (from-to)S58-S63
JournalAlzheimer disease and associated disorders
Issue number4
StatePublished - Oct 2007


  • Clinical trials
  • Frontotemporal lobar degeneration
  • Longitudinal studies
  • Primary progressive aphasia

ASJC Scopus subject areas

  • Clinical Psychology
  • Gerontology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health


Dive into the research topics of 'Longitudinal tracking of FTLD: Toward developing clinical trial methodology'. Together they form a unique fingerprint.

Cite this